MN
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 (NCT02682407) | Omeros Corporation | 2016-03-10 |
Track MN automatically
Every clearance here is in the API, with alerts when new ones post.